Neuroectodermal Tumors: Clinical Trials

9 trials for Neuroectodermal Tumors, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 enrolling by invitation. 9 Phase 1, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 19Enrolling by invitation 9
Phase 25Enrolling by invitation 5

Follow Neuroectodermal Tumors: new trials by email Literature Review of Neuroectodermal Tumors trials Research Report on Neuroectodermal Tumors

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
Nivolumab, Azacitidine (AZA), lumbar puncture - Glioblastoma (GBM), Diffuse Midline Glioma (DMG)
Phase 1Enrolling by invitationAndrew P. Groves342025-06-052026-10-27
Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma
Novel oncolytic virus Ad-TD-nsIL12 - Glioma
Phase 1 / Phase 2Enrolling by invitationXiaorong Wu402025-02-122026-03-23
Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.
BioTTT001 injection - Recurrent High-grade Glioma
Phase 1 / Phase 2Enrolling by invitationBeijing Bio-Targeting Therapeutics Technology Co., Ltd302024-11-262026-03-23
A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma
AK104+Axitinib, AK112+Axitinib - Melanoma, Mucosal Melanoma
Phase 1Enrolling by invitationPeking University Cancer Hospital & Institute602024-05-282026-07-13
Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
PET/CT ([18F]AlF-NOTA-PCP2), [18F]AlF-NOTA-PCP2 PET/CT Imaging for PD-L1 Expression in Malignant Tumors - Glioblastoma (GBM), Head and Neck Squamous Cell Carcinoma
Phase 1 / Phase 2Enrolling by invitationMan Hu1002024-03-302025-03-30
The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM
SNC109 - Recurrent Glioblastoma Multiforme (GBM)
Phase 1Enrolling by invitationShanghai Simnova Biotechnology Co.,Ltd.502023-12-262024-09-27
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
GPC2 CAR T cells - Refractory Neuroblastoma, Relapsed Neuroblastoma
Phase 1Enrolling by invitationStephan Grupp MD PhD452023-05-232026-08-14
Melphalan Chemoreduction for Ocular Melanoma
Melphalan Injection, Plaque brachytherapy - Uveal Melanoma
Phase 1 / Phase 2Enrolling by invitationHospital das Clínicas de Ribeirão Preto102021-05-012025-09-15
The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells
cytokine induced killer cells - Cholangiocarcinoma, Neuroblastoma
Phase 1 / Phase 2Enrolling by invitationSiriraj Hospital202009-04-172025-02-10

Narrower conditions

Glioblastoma (3)  ·  Glioma (2)  ·  Melanoma (2)  ·  Neuroblastoma (2)  ·  Adenoviridae Infections (1)  ·  Astrocytoma (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Cholangiocarcinoma (1)  ·  Esophageal Neoplasms (1)  ·  Retinoblastoma (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)  ·  Uveal Melanoma (1)

Broader conditions

Neoplasms (9)  ·  Neoplasms by Histologic Type (9)  ·  Neoplasms, Germ Cell and Embryonal (9)  ·  Neoplasms, Nerve Tissue (9)  ·  Neoplasms, Glandular and Epithelial (7)  ·  Neoplasms, Neuroepithelial (7)  ·  Neoplasms by Site (4)  ·  Glioma (3)  ·  Astrocytoma (2)  ·  Carcinoma (2)  ·  Eye Diseases (2)  ·  Eye Neoplasms (2)  ·  Neuroectodermal Tumors, Primitive (2)  ·  Neuroectodermal Tumors, Primitive, Peripheral (2)

Interventions

Azacitidine (1)  ·  Brachytherapy (1)  ·  Melphalan (1)  ·  Nivolumab (1)  ·  Radiotherapy (1)  ·  Ruthenium-106 (1)  ·  Spinal Puncture (1)

Sponsors

Andrew P. Groves (1)  ·  Beijing Bio-Targeting Therapeutics Technology Co., Ltd (1)  ·  Hospital das Clínicas de Ribeirão Preto (1)  ·  Man Hu (1)  ·  Peking University Cancer Hospital & Institute (1)  ·  Shanghai Simnova Biotechnology Co.,Ltd. (1)  ·  Siriraj Hospital (1)  ·  Stephan Grupp MD PhD (1)  ·  Xiaorong Wu (1)

Countries

China (5)  ·  United States (2)  ·  Brazil (1)  ·  Thailand (1)

Top investigators

Adisak Wongkajornsilp, M.D., Ph.D. (1)  ·  Jun Guo, MD (1)  ·  Lisa Wray, MD (1)  ·  Man Hu, Dr. (1)  ·  Rodrigo Jorge, MD, PhD (1)

Results publications

PMID 38291578, PMID 38713298, PMID 41026583

NIH funding

R37CA282041 (1)